Literature DB >> 23289731

Differential regulation of inflammation by inflammatory mediators in cystic fibrosis lung epithelial cells.

Motohiro Tsuchiya1, Parameet Kumar, Sharmistha Bhattacharyya, Sangbrita Chattoraj, Meera Srivastava, Harvey B Pollard, Roopa Biswas.   

Abstract

Cystic fibrosis (CF) is due to mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which cause a massively proinflammatory phenotype in the CF airway. The chemical basis of the inflammation is hyperproduction of interleukin-8 (IL-8) by CF airway epithelial cells, based on both an intrinsic mutation-dependent mechanism and by infection. In infection-free, cultured CF lung epithelial cells, high levels of the microRNA (miR), miR-155, is responsible for hyperexpression of IL-8. However, whether infection-induced IL-8 expression in CF cells is also mediated by miR-155 is not known. We have hypothesized that miR-155 might be a general mediator of enhanced IL-8 expression in CF cells, either in response to other cytokine/chemokine mediators of inflammation, or after exposure to infectious agents. Here we find that a reduction in miR-155 accompanies suppression of IL-8 by either the anti-inflammatory cytokine IL-10 or by inhibition of ambient IL-1β with a neutralizing antibody. However, attempts to elevate IL-8 levels with either intact bacteria [viz. a mucoid strain of Pseudomonas aeruginosa (PA)], or lipopolysaccharide were unable to elevate miR-155 above its intrinsically high level in the absence of these agents. Instead, in response to PA infection, the CF cells modestly suppress the expression of miR-155, and express a novel set of miRs, including miR-215. We find that ex vivo CF lung epithelial cells also express high levels of both miR-155 and miR-215. The predicted module of infection-induced mRNA targets focuses on activation of the NFκB-signaling pathway, and on the proapoptotic p53-signaling pathway. We interpret these data to suggest that that CF lung epithelial cells respond to PA or bacterial cell products with a novel miR program that may carry with it serious challenges to survival.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23289731     DOI: 10.1089/jir.2012.0074

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  14 in total

1.  Cystic Fibrosis Plasma Blunts the Immune Response to Bacterial Infection.

Authors:  Xi Zhang; Amy Pan; Shuang Jia; Justin E Ideozu; Katherine Woods; Kathleen Murkowski; Martin J Hessner; Pippa M Simpson; Hara Levy
Journal:  Am J Respir Cell Mol Biol       Date:  2019-09       Impact factor: 6.914

Review 2.  MicroRNA-155: A Master Regulator of Inflammation.

Authors:  Guruswamy Mahesh; Roopa Biswas
Journal:  J Interferon Cytokine Res       Date:  2019-03-20       Impact factor: 2.607

3.  RPTOR, a novel target of miR-155, elicits a fibrotic phenotype of cystic fibrosis lung epithelium by upregulating CTGF.

Authors:  Motohiro Tsuchiya; Swathi Kalurupalle; Parameet Kumar; Sarani Ghoshal; Yongqing Zhang; Elin Lehrmann; Kevin G Becker; Myriam Gorospe; Roopa Biswas
Journal:  RNA Biol       Date:  2016-06-10       Impact factor: 4.652

4.  Colonization of CF patients' upper airways with S. aureus contributes more decisively to upper airway inflammation than P. aeruginosa.

Authors:  Wibke Katharina Janhsen; Christin Arnold; Julia Hentschel; Thomas Lehmann; Wolfgang Pfister; Michael Baier; Klas Böer; Kerstin Hünniger; Oliver Kurzai; Uta-Christina Hipler; Jochen Georg Mainz
Journal:  Med Microbiol Immunol       Date:  2016-07-04       Impact factor: 3.402

Review 5.  Biomarkers in Cystic Fibrosis Lung Disease - A Review.

Authors:  Ioana Mihaiela Ciuca; Paula Marian; Marc Monica
Journal:  Rom J Anaesth Intensive Care       Date:  2020-10-11

Review 6.  Novel insights into miRNA in lung and heart inflammatory diseases.

Authors:  Amit Kishore; Jana Borucka; Jana Petrkova; Martin Petrek
Journal:  Mediators Inflamm       Date:  2014-05-27       Impact factor: 4.711

7.  Prediction of miRNA-disease associations with a vector space model.

Authors:  Claude Pasquier; Julien Gardès
Journal:  Sci Rep       Date:  2016-06-01       Impact factor: 4.379

Review 8.  Airway Epithelium Dysfunction in Cystic Fibrosis and COPD.

Authors:  Virginia De Rose; Kevin Molloy; Sophie Gohy; Charles Pilette; Catherine M Greene
Journal:  Mediators Inflamm       Date:  2018-04-08       Impact factor: 4.711

9.  Phage therapy against Pseudomonas aeruginosa infections in a cystic fibrosis zebrafish model.

Authors:  Marco Cafora; Gianluca Deflorian; Francesca Forti; Laura Ferrari; Giorgio Binelli; Federica Briani; Daniela Ghisotti; Anna Pistocchi
Journal:  Sci Rep       Date:  2019-02-06       Impact factor: 4.379

Review 10.  The EGFR-ADAM17 Axis in Chronic Obstructive Pulmonary Disease and Cystic Fibrosis Lung Pathology.

Authors:  Marta Stolarczyk; Bob J Scholte
Journal:  Mediators Inflamm       Date:  2018-01-09       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.